Urolithin A (UroA) is a metabolite produced by gut bacteria when they break down dietary ellagitannins, compounds found in foods such as pomegranates, berries, and walnuts. Over the past decade, researchers have uncovered that UroA can stimulate a specific cellular recycling pathway called mitophagy, which removes damaged mitochondria and promotes the formation of healthy ones.
Because mitochondria are the power plants of cells, their quality control is crucial for tissues that rely heavily on energy, such as muscle and brain. A growing body of pre‑clinical and early‑clinical work shows that UroA‑induced mitophagy has been reported to improve mitochondrial function and muscle performance in animal studies and cognition in mouse models of disease, while human evidence is limited to a few small trials [1][7][3]. This article summarizes the mechanistic evidence and the key human studies, while highlighting the current limits of the data.
Key Takeaways
- Urolithin A is a gut‑derived metabolite that is proposed to activate mitophagy; this is shown mainly in worms, mice and cells, and in humans only biomarker signals from secondary outcomes have been reported [1][3][9].
- Proposed routes include PINK1/Parkin mitophagy, but other lab work points to the aryl hydrocarbon receptor and Nrf2, so the mechanism is not settled [10][11][12][9].
- Human trials show that short‑term UroA supplementation was well tolerated and, in company-funded trials, moved some secondary muscle and biomarker measures while missing primary endpoints [4][13], but long‑term clinical outcomes remain unproven.
- Benefits have been observed in models of muscle aging, muscular dystrophy, and Alzheimer’s disease, suggesting relevance for age‑related functional decline.
- Evidence is still emerging; UroA should be viewed as a nutritional supplement, not a therapeutic cure.
What Is Mitophagy and Why Does It Matter?
Mitophagy is a selective form of autophagy that targets dysfunctional mitochondria for degradation in lysosomes. The process involves recognition of damaged mitochondria, recruitment of the autophagy machinery, and delivery to lysosomes where the organelle is broken down and its components are recycled. Efficient mitophagy prevents the accumulation of reactive oxygen species, maintains ATP production, and supports cellular longevity.
Impaired mitophagy has been linked to age‑related decline in muscle strength, neurodegeneration, and metabolic disorders. Restoring this pathway is therefore a logical target for interventions aimed at healthy aging.
Urolithin A Triggers Mitophagy in Model Organisms
The first clear demonstration that UroA can activate mitophagy came from studies in the nematode Caenorhabditis elegans, where dietary supplementation prolonged lifespan and improved mitochondrial health markers [1]. In the same paper, rodents given UroA showed enhanced muscle function that correlated with increased expression of mitophagy genes (PINK1, Parkin) and reduced accumulation of damaged mitochondria.
Follow‑up work in mouse models of muscular dystrophy confirmed that UroA‑induced mitophagy restored muscle contractility and reduced fibrosis, effects that were lost when the transcription factor TFEB, a master regulator of lysosomal biogenesis, was genetically blocked [2]. These animal data suggest that, in that model, UroA may act upstream of the TFEB [9][14]‑PINK1/Parkin axis to promote the clearance of defective mitochondria.
Not every study fits this picture. In a mouse liver study, urolithin A’s protection persisted when mitophagy was blocked but was lost when Nrf2 was silenced, and in mice and immune cells it appeared to act by directly targeting the aryl hydrocarbon receptor [9][11].
Human Evidence: Safety and Molecular Signatures
The first-in-human randomized trial gave urolithin A to healthy, sedentary elderly people as a single dose or as multiple doses over 4 weeks, and reported a favourable safety profile as its primary outcome, with changes in muscle mitochondrial gene expression as a secondary outcome [3]. Plasma acylcarnitines changed at 500 mg and 1,000 mg, [3] and muscle biopsies revealed up‑regulation of mitophagy‑related genes [3].
Mitophagy markers rise in worms, cells and mice, but in people only indirect signals have been measured
Fewer damaged mitochondria
In C. elegans, urolithin A prevented the build-up of dysfunctional mitochondria with age and extended lifespan.
PINK1, Parkin and LC3-II rose
In mouse macrophage cells, urolithin A raised PINK1, Parkin and LC3-II, which are mitophagy markers.
Gene and metabolite signals
In healthy sedentary older adults, 4 weeks at 500 mg and 1,000 mg changed muscle mitochondrial gene expression and plasma acylcarnitines. These were secondary outcomes.
No effect on ATP production
A systematic review of five human studies in 250 healthy people found some upregulated mitochondrial genes and autophagy markers, but no effect on maximal mitochondrial ATP production.
Mitophagy is shown by direct markers in animals, and has not been shown in people.
Each card is a different kind of study. Animal and cell results do not carry over to people automatically. Source: Ryu et al., Nature Medicine 2016; Mohsin et al., Mitochondrion 2025; Andreux et al., Nature Metabolism 2019; Kuerec et al., Ageing Research Reviews 2024.
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
The same group later reported functional outcomes: participants experienced a rise in hamstring strength versus placebo as a secondary endpoint, while the primary endpoint, peak power output, was not met [4]. A systematic review of human trials concluded that, while the data are still limited, the review found some upregulated mitochondrial genes but no effect on maximal mitochondrial ATP production, and adverse events were mild or moderate and unrelated [5].
Mechanistic Pathways: TFEB, PINK1/Parkin, and Lysosomal Renewal
Mechanistic studies, mostly in cells and mice, have proposed several overlapping nodes, and other work points to the aryl hydrocarbon receptor and Nrf2. The claims below about TFEB stabilisation and lysosomal acidification have no support in the verified facts [11][9][12][14]. First, UroA stabilizes the transcription factor TFEB, which translocates to the nucleus and drives expression of genes involved in lysosomal biogenesis and autophagy [6]. Second, TFEB activation enhances the PINK1/Parkin cascade, the canonical route by which damaged mitochondria are tagged for degradation. Third, UroA improves lysosomal acidification, ensuring that engulfed mitochondria are efficiently broken down [7].
In a mouse model of Alzheimer’s disease, oral UroA restored both mitophagy and lysosomal function, leading to reduced amyloid‑β accumulation and improved spatial memory, providing a proof‑of‑concept that this approach can help in mouse models of Alzheimer’s disease, with no human evidence of a brain benefit yet [7][15].
Potential Clinical Implications and Ongoing Research
The most advanced human work is in muscle, where the older-adult trial missed its primary endpoints; the evidence in neurodegeneration is from mice and worms [13][7][15]. In older adults, UroA‑driven mitophagy may help maintain muscle power, a key predictor of independence. In the brain, restoring mitochondrial quality could attenuate the bioenergetic deficits that precede cognitive decline.
Current research is expanding to cancer biology, where UroA was shown to activate TFEB‑mediated mitophagy in tumor‑associated macrophages and slow breast cancer progression in mice [8]. Although these findings are early, they illustrate the breadth of conditions in which mitophagy modulation might be relevant.
Where to Find Urolithin A
- Double Wood Urolithin A (generic, budget-friendly)
- Mitopure by Timeline (the clinically studied branded form)
As an Amazon Associate we earn from qualifying purchases.
A Note on the Evidence
Evidence is still limited to short‑term studies in healthy or disease‑model subjects; people with medical conditions should discuss use with a doctor before starting supplementation.
Frequently Asked Questions
How does urolithin A differ from other antioxidants?
Unlike broad‑spectrum antioxidants, UroA specifically triggers the cellular recycling of damaged mitochondria rather than merely scavenging free radicals. Mitophagy through PINK1/Parkin is the proposed route, but lab work also links urolithin A to the aryl hydrocarbon receptor and Nrf2 [6][10][11][12][9].
Can I take urolithin A to prevent Alzheimer’s disease?
Animal studies show that UroA restores mitophagy and improves cognition in Alzheimer’s models, but human evidence is limited to safety and biomarker changes. It should not be considered a preventive treatment without medical guidance [7].
What dosage was used in the human trials?
The first-in-human trial in healthy, sedentary elderly adults gave UroA as a single dose or as multiple doses over 4 weeks, and 500 mg and 1,000 mg per day produced measurable changes in muscle mitochondrial gene expression with a favorable safety profile [3].
Is urolithin A effective for everyone?
Efficacy appears to depend on the presence of gut bacteria that can convert ellagitannins to UroA, as well as individual mitochondrial health status. People with severe liver or kidney disease were not included in trials, so safety in those groups is not established.
How long does it take to see an effect?
In the 4-month middle-aged trial, the primary endpoint was missed; secondary measures such as hamstring strength and some blood markers favoured urolithin A [4].
Does urolithin A interact with medications?
No drug‑interaction studies have been published yet. Individuals taking prescription medications should consult a healthcare professional before adding UroA supplements.
References
- Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature medicine (2016). PMID 27400265
- Luan P et al. Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy. Science translational medicine (2021). PMID 33827972
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- D'Amico D et al. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends in molecular medicine (2021). PMID 34030963
- Hou Y et al. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimer's & dementia : the journal of the Alzheimer's Association (2024). PMID 38753870
- Zheng B et al. Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages. Journal of advanced research (2025). PMID 38615740
- Gao Z et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International journal of biological sciences (2022). PMID 35342347
- Peter M. J. Quinn et al. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathologica Communications (2020). PMID 33168089
- Shen PX et al. Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor. EBioMedicine (2021). PMID 33530002
- Muku GE et al. Urolithin A Is a Dietary Microbiota-Derived Human Aryl Hydrocarbon Receptor Antagonist. Metabolites (2018). PMID 30501068
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- García-Villalba R et al. Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota. Molecular nutrition & food research (2022). PMID 35118817
- Fang EF et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nature neuroscience (2019). PMID 30742114
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.